Kathmere Capital Management LLC Buys 4,272 Shares of Johnson & Johnson $JNJ

Kathmere Capital Management LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 43,808 shares of the company’s stock after purchasing an additional 4,272 shares during the quarter. Kathmere Capital Management LLC’s holdings in Johnson & Johnson were worth $10,708,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Sierra Capital LLC increased its position in Johnson & Johnson by 0.5% during the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock valued at $1,685,000 after acquiring an additional 41 shares during the last quarter. Beaird Harris Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 1.8% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after acquiring an additional 42 shares during the last quarter. Broadleaf Partners LLC boosted its stake in shares of Johnson & Johnson by 0.6% during the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock worth $1,521,000 after purchasing an additional 43 shares during the period. Jessup Wealth Management Inc boosted its stake in shares of Johnson & Johnson by 0.6% during the 4th quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock worth $1,567,000 after purchasing an additional 44 shares during the period. Finally, Plancorp LLC grew its holdings in Johnson & Johnson by 0.3% during the 4th quarter. Plancorp LLC now owns 15,889 shares of the company’s stock valued at $3,288,000 after purchasing an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on JNJ. HSBC set a $290.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Monday. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $265.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Citigroup increased their price target on Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Finally, Stifel Nicolaus upped their price objective on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $257.74.

Johnson & Johnson Stock Performance

JNJ stock opened at $263.52 on Thursday. Johnson & Johnson has a 1-year low of $154.80 and a 1-year high of $269.43. The business has a 50-day moving average price of $235.85 and a 200 day moving average price of $232.52. The company has a market capitalization of $634.34 billion, a P/E ratio of 30.46, a PEG ratio of 2.62 and a beta of 0.24. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is 61.97%.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced FDA approval for its dual-energy THERMOCOOL SMARTTOUCH SF platform, a positive catalyst that could support growth in the company’s medtech business and improve investor confidence in its pipeline. Article Title
• Positive Sentiment: The stock had recently been pushing to record highs as analysts raised price targets and investors responded to a higher outlook and pre-earnings optimism, suggesting the long-term setup for JNJ remains constructive. Article Title
• Neutral Sentiment: Commentary this week also highlighted JNJ as a defensive healthcare name with steady cash flow, while other pieces focused on valuation, earnings expectations, and healthcare sector comparisons rather than new company-specific setbacks. Article Title
• Negative Sentiment: Despite the positive product news, some trading-focused coverage noted unusual put option activity after the recent run-up, indicating that a portion of the market is positioning for a possible pullback. Article Title
• Negative Sentiment: One market recap also described JNJ as declining more than the broader market, reinforcing the idea that the stock is pausing after a strong advance rather than reacting to a major fundamental problem. Article Title

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.